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Neuromyelitis optica (NMO) is an autoimmune disease in which a specific biomarker named NMO-IgG and directed against
aquaporin-4 (AQP4) has been found. A correlation between disease activity and anti-AQP4 antibody (Ab) serum concentration or
complement-mediated cytotoxicity has been reported, but the usefulness of longitudinal evaluation of these parameters remains
to be evaluated in actual clinical practice. Thirty serum samples from 10NMO patients positive for NMO-IgG were collected from
2006 to 2011. Anti-AQP4 Ab serum concentration and complement-mediated cytotoxicity were measured by flow cytometry using
two quantitative cell-based assays (CBA) and compared with clinical parameters. We found a strong correlation between serum
anti-AQP4 Ab concentration and complement-mediated cytotoxicity (𝑃 < 0.0001). Nevertheless, neither relapse nor worsening
of impairment level was closely associated with a significant increase in serum Ab concentration or cytotoxicity. These results
suggest that complement-mediated serum cytotoxicity assessment does not provide extra insight compared to anti-AQP4Ab serum
concentration. Furthermore, none of these parameters appears closely related to disease activity and/or severity. Therefore, in
clinical practice, serum anti-AQP4 reactivity seems not helpful as a predictive biomarker in the followup of NMO patients as a
means of predicting the onset of a relapse and adapting the treatment accordingly.
1. Introduction
Neuromyelitis optica (NMO) is a severe inflammatory de-
myelinating disease of the central nervous system in which
inflammatory lesions are usually restricted to the spinal cord
and optic nerves [1, 2]. NMO is distinguished from multiple
sclerosis (MS) by a more severe evolution and a predominant
humoral response [3]. A highly disease-specific serum anti-
body (Ab), NMO immunoglobulin G (NMO-IgG), has been
recently discovered [4]. The target antigen of NMO-IgG was
identified as aquaporin-4 (AQP4), the main water channel
protein in the CNS [5]. Owing to its very high specificity in
NMO, anti-AQP4 Ab was included in the revised diagnostic
criteria for NMO [6]. Anti-AQP4 Ab also proved to be
helpful in predicting a more severe course and a probable
conversion to NMO after a first episode of isolated optic
neuritis or longitudinally extensive transverse myelitis [7–
11]. Several experiments in animal models demonstrated a
pathogenic role of this antibody in the disease [12–14].There-
after, it was questioned whether anti-AQP4 Ab serum con-
centration is related to disease activity in humans and, thus,
whether its assessment could be helpful in predicting disease
evolution and adapting the treatment.
A link between anti-AQP4 serum reactivity and vari-
ous clinical parameters in NMO patients was suggested by
numerous studies. Takahashi et al. found an association
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between high anti-AQP4 Ab serum concentration and both
transverse myelitis lesion length and disease activity [15].
Accordingly, Jarius et al. [16] and Waters et al. [17] described
increased anti-AQP4 serum concentration during clinical
relapses and a decrease following immunosuppressive ther-
apy. Kim et al. suggested that anti-AQP4 Ab levels correlate
with disease activity but noted that rising of anti-AQP4-Ab
levels did not always lead to acute exacerbation [18]. However,
when testing complement-dependant cytotoxic properties of
NMO patients’ serum on AQP4 transfected cells, Hinson et
al. observed that severe relapses were associated with higher
cytotoxicity but not higher anti-AQP4 serum concentration
[19]. Finally, Dujmovic et al. found that cerebrospinal fluid
(CSF) but not serum anti-AQP4 Ab titers are associated with
disease activity and neuroinflammation [20], whereas Jarius
et al. suggested that both parameters are correlated with
relapses [21].
Here, we aimed to evaluate the interest of a longitudinal
assessment of anti-AQP4Ab in clinical practice.We therefore
compared the evolution of both anti-AQP4 Ab serum con-
centration and complement-mediated cytotoxicity with key
clinical parameters such as relapse onset and disease severity.
2. Patients and Methods
2.1. Patients. Among the NMO patients followed up in the
Neurology Department of the University Hospital of Stras-
bourg, we selected those who were positive for NMO-IgG.
The disease was diagnosed according to the revised criteria of
Wingerchuk et al. [6]. NMO-IgGs were detected by indirect
immunofluorescence (IIF) on primate cerebellum slides with
diluted sera (1/50) following the manufacturer’s instruc-
tions (Instrumentation Laboratory, Lexington, MA, USA).
Patients must have presented at least one relapse in the 5
last years. Ten NMO patients were included. We collected
both retrospectively and prospectively serum samples taken
during a relapse or a control visit. Presence of a relapse and
disease severity (evaluated by the Expanded Disability Status
Scale, EDSS) at the time of the blood draw were registered.
Relapses were treated at least with intravenous high-dose
methylprednisolone (1000mg/day over 3–5 days) and for
the most severe relapses with plasma exchanges (PE, 4-5 PE
cycles). The samples were taken before corticosteroid treat-
ment or PE.The interval between the onset of the relapse and
the blood draw was from three to seven days. Presence of an
immunosuppressive therapy (cyclophosphamide, mycophe-
nolate mofetil, azathioprine, mitoxantrone, or rituximab)
was also registered. Written informed consent was obtained
from all patients. Study protocol was declared to the CNIL
(Commission Nationale Informatique et Liberte´s), and the
studywas performed in accordancewith the ethical standards
laid down in the 1964 Declaration of Helsinki.
2.2. Measurement of Anti-AQP4 Ab Serum Concentration.
Sera were collected between 2006 and 2011 and stored at
−80∘C. They were sent to the Department of Immunology of
the University Hospital of Montpellier (France). Anti-AQP4
Ab serum concentration was measured without knowledge
of clinical information using a new quantitative cell-based
assay (CBA) recently validated [22]. Briefly, HEK-293 T
human cell line was transduced using HIV-based vectors
expressing either the human AQP4 and enhanced green
fluorescent protein (EGFP) genes (293-AQP4/EGFP cells) or
the EGFP gene alone (293-EGFP cells). Cells were incubated
with diluted human sera (1/200) in FACS buffer (PBS con-
taining 1% fetal calf serum and 0.1% sodium azide), washed,
and incubated with allophycocyanin- (APC-)conjugated goat
anti-human IgGAb (Jackson ImmunoResearch Laboratories,
West Grove, USA). After washes, cells were analyzed on a
FACSCalibur (BDBiosciences), andAPC-mean fluorescence
intensity (MFI) was measured on EGFP positive cells. A
serum was considered anti-AQP4 positive if it bound 293-
AQP4/EGFP but not 293-EGFP cells. To determine the anti-
AQP4 concentration (arbitrary units; AU/mL), the APC-
MFI of 293-AQP4/EGFP cells incubated with 1/200 diluted
patient sera and corrected for the background binding to the
293-EGFP control cells was plotted on a calibration curve
obtained with a pool of NMO-IgG positive sera diluted from
1/200 (1000AU/mL) to 1/51200 (3.9 AU/mL). All sera from
the same patient were analyzed simultaneously.
2.3. Measurement of Complement-Mediated Serum Cytotox-
icity. The protocol was inspired from Hinson et al. [19].
293-AQP4/EGFP and 293-EGFP cells were incubated with
patients’ sera (20% serum in FACS buffer for 30 minutes at
+4∘C). After washes, cells were incubated with active comple-
ment (40% complement for 45 minutes at 37∘C; Low-Tox-H
rabbit complement; Cedarlane Laboratories Ltd, Burlington,
NC, USA) and complement-dependent cytotoxicity (CDC)
wasmeasured by flow cytometric analysis of the percentage of
EGFP positive cells permeable to the viability dye propidium
iodide (PI). A pool of normal sera from healthy subjects
was included in each experiment as a negative control.
Serum cytotoxicity was defined (AU/mL) by the difference
between the percentage of PI positive cells induced in 293-
AQP4/EGFP cells versus 293-EGFP cells corrected by the
background of mortality obtained with the pool of normal
sera. All sera from the same patient were analyzed simultane-
ously.
2.4. Statistical Analysis. The Pearson correlation coefficient
was used to search for a correlation between anti-AQP4 Ab
serum concentration and cytotoxicity. The nonparametric
Mann-Whitney 𝑈 test was used to determine whether anti-
AQP4 serum concentration or cytotoxicity was related to the
presence of a relapse or disease severity. We compared both
biological parameters in samples taken in relapsing phase
(<1 month after a relapse) versus remitting phase and in the
5 more disabled patients (i.e., with the highest mean EDSS
scores) versus the other ones. A Bonferroni correction for
multiple comparisons was applied and the statistical signif-
icance was defined as 𝑃 value of 𝑃 < 0.01.
3. Results
3.1. Patients. Thirty sera were collected from 10 NMO-IgG
positive patients (mean: 3 per patient, range 2–5) between
2006 and 2011. Patients’ characteristics are summarized in
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Table 1: Clinical features of NMO patients.
Patient number Age (yrs) Disease duration (yrs) Follow-up duration (mo) EDSS Immunosuppressive treatment
1 54 4 31 0 AZT
2 19 2 37 2.5 AZT
3 38 6 53 1.5 MMF
4 61 1 35 2 None
5 19 1 30 3 AZT
6 63 12 14 8 MTX then AZT
7 27 3 6 3.5 RTX
8 46 0.1 2.5 4 CYC
9 62 1.5 0.5 5.5 PE
10 54 1 6 3.5 AZT
Mean ± SD 44.3 ± 17.5 3.2 ± 3.8 26.5 ± 16 3.4 ± 3
yrs: years; mo: months; disease duration: duration from the first symptom of the disease to the first blood draw; follow-up duration: duration from the first to
the last blood draw; EDSS: EDSS score evaluating disease severity; AZT: azathioprine; MMF: mycophenolate mofetil; RTX: rituximab; MTX: mitoxantrone;
CYC: cyclophosphamide; PE: plasma exchanges.
Table 2: Relationship between anti-AQP4 Ab serum concentrations, complement-mediated cytotoxicity, and clinical parameters.
Anti-AQP4 concentration (AU/mL) P Serum cytotoxicity (AU/mL) P
Patients during a relapse 124 ± 127
𝑃 = 0.71
13.5 ± 12
𝑃 = 0.89
Patients during a remitting phase 176 ± 224 14.2 ± 11
Patients with the more severe impairment 94 ± 52
𝑃 = 0.38
10.2 ± 7.7
𝑃 = 0.21
Patients with the milder impairment 208 ± 248 17 ± 13
Anti-AQP4 Ab serum concentration and complement-mediated serum cytotoxicity were measured in 30 sera from 10 NMO patients with a cell-based assay as
described in methods. We compared both biological parameters in samples taken in relapsing phase (<1 month after a relapse) versus remitting phase and in
the 5 more disabled patients (i.e., with the highest EDSS scores) versus the other ones. P: alpha risk.
Table 1. All were women. Ten samples (33%) were taken
during a relapse. The mean interval between two samplings
was 10.7 ± 8 months (mean ± standard deviation).
3.2. Evaluation of Anti-AQP4 Ab Serum Concentration
and Complement-Dependent Cytotoxicity. As some studies
described discrepancies between anti-AQP4 Ab serum con-
centration and complement-dependent cytotoxicity, wemea-
sured and compared these parameters in different NMO
patients’ sera. Mean anti-AQP4 Ab serum concentration was
158 ± 136 AU/mL (range 132–>1000) and mean cytotoxicity
was 14.1 ± 11 AU/mL (range 0–38.8). We observed a high
intra- and interindividual variability especially in anti-AQP4
Ab serum concentration. However, as shown in Figure 1,
serum anti-AQP4 Ab concentration and complement-de-
pendent cytotoxicity were highly correlated (𝑟 = 0.87, 𝑃 <
0.0001).
3.3. Relationships between Biological and Clinical Parame-
ters. Detailed anti-AQP4 reactivity course was compared to
relapse onset, EDSS changes, and treatment for each patient
as shown in Figures 2 and 3. As summarized in Table 2, we
did not observe any significant correlation between biological
parameters and disease activity. Indeed, increase in anti-
AQP4 Ab concentration may occur with no clinical change
(e.g., patient 1), and conversely disease worsening was often
not accompanied by an increase in anti-AQP4 Ab levels
(patients 2 and 3). A significant effect of immunosuppres-
sant was noted on anti-AQP4 Abs concentration. Indeed,
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Figure 1: Correlation between serum anti-AQP4 Ab concentration
and serum complement- (𝐶󸀠-)mediated cytotoxicity. Anti-AQP4Ab
serum concentration and complement- (𝐶󸀠-)mediated serum cyto-
toxicity were measured in 30 sera from 10 NMO patients with a cell-
based assay using AQP4 expressing human 293 T cells and flow
cytometry. Results are expressed in arbitrary units (AU/mL). The
Pearson correlation coefficient (𝑟) was 0.87 (𝑃 < 0.0001).
mycophenolate mofetil initiation was concomitant with a
marked decreased anti-AQP4 reactivity in patient 3. A less
significant decrease was observed under azathioprine in
patient 2 and under cyclophosphamide in patient 6. Plasma
exchanges resulted in a rapid anti-AQP4 reactivity decline
(patient 9). However, a similar effect was not observed under
azathioprine in patients 1 and 6. Rituximab initiation in
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Figure 2: Detailed evolution of anti-AQP4 serum reactivity and comparison with disease course in patients 1 to 6. Serum anti-AQP4 Ab
concentration (black triangle)wasmeasuredwith a cell-based assay usingAQP4 expressing human 293T cells andflow cytometry as described
in Section 2. EDSS score indicates the level of impairment (grey circle); vertical dashed arrows represent relapses (all relapses were treatedwith
corticosteroids); horizontal arrows indicate a treatment (AZA: azathioprine; CX: monthly administration of IV corticoids; INF B: interferon
beta; MMF: mycophenolate mofetil; PE: plasma exchange; MTX: mitoxantrone).
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Figure 3: Detailed evolution of anti-AQP4 serum reactivity and comparison with disease course in patients 7 to 10. Serum anti-AQP4
Ab concentration (black triangle) was measured with a cell-based assay using AQP4 expressing human 293 T cells and flow cytometry as
described in Section 2. EDSS score indicates the level of impairment (grey circle); vertical dashed arrows represent relapses (all relapses were
treated with corticosteroids); horizontal arrows indicate a treatment (RTX: rituximab (1 perfusion weekly of 375mg/m2 during 4 weeks);
CYC: cyclophosphamide; PE: plasma exchange; AZA: azathioprine).
patient 7 resulted in an early increase (with no clinical event)
followed by a delayed decrease (at 6 months) in anti-AQP4
reactivity.
As shown in Table 2, statistical analysis found no rela-
tionship between anti-AQP4 serumconcentration or comple-
ment-mediated cytotoxicity and the presence of a relapse or
disease severity (EDSS score).
4. Discussion
The followup of our patients suggests that anti-AQP4 Ab
serum concentration and complement-mediated cytotoxicity
are strongly correlated, but that their monitoring does not
allow an accurate and reliable prediction of disease evolution.
The only study that longitudinally assessed serum com-
plement-mediated cytotoxicity in NMO patients reported
that this parameter was better correlated with disease activity
than anti-AQP4 Ab serum concentration [19].These findings
were not in accordance with the marked link previously
demonstrated in vitro between anti-AQP4 Ab concentration
and complement-dependent cytotoxicity [23, 24]. In our
patients, despite high inter- and intraindividual variability,
we found amarked correlation between anti-AQP4Ab serum
concentration and complement-mediated serum cytotoxicity
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(𝑃 < 0.0001).This result suggests thatmeasurement of serum
cytotoxicity does not give an extra insight compared to anti-
AQP4Ab concentration assessment. Accordingly, when com-
pared with disease course or severity, anti-AQP4 Ab serum
concentration and complement-mediated cytotoxicity gave
very similar and nonsignificant results.
NMO is characterized by severe relapses often resulting in
sustained functional impairment and it would be of particular
interest to predict a relapse onset for an earlier adaptation
of the treatment [25]. Unfortunately, in the followup of our
patients, relapses were rarely associatedwith relevant changes
in anti-AQP4 reactivity. This is well illustrated by patients
2 and 3 in which anti-AQP4 reactivity was lower during a
relapse than a remitting phase. Conversely, we observed in
other cases thatmarked changes in anti-AQP4 reactivity were
not accompanied by any clinical event (e.g., patient 1). A
potential confounding factor was the presence of immuno-
suppressive therapies which are often prescribed in NMO
[15, 16]. We frequently observed a decrease in anti-AQP4 Ab
concentration after the beginning of an immunosuppressive
treatment. However, this effect was not systematic as was
shown in patients 1 and 6. Transient increase in anti-AQP4
reactivity observed after Rituximab initiation in patient 7 is
consistent with those reported in two recent papers [26, 27].
Interestingly, these studies did not observe any correlation
between the increase in anti-AQP4 Ab serum concentration
and the worsening of the disease.
Our results do not preclude a pathogenic role of serum
anti-AQP4 Ab in NMO but underline the requirement of
additional factors to allow peripheral Abs to cross the blood-
brain barrier (BBB) and gain their targets in the CNS. Indeed,
theworsening of experimental autoimmune encephalitis after
intraperitoneal injection of anti-AQP4 Abs in animal was
dependant on a previous BBB breakdown and the presence of
inflammatory cytokines [12]. Likewise, intrathecal or intrac-
erebral injection of NMO-IgG in the CNS induces NMO-
like lesions, whereas peripheral injection does not cause
CNS damage [14]. Indeed, although tolerance breakdown is
thought to occur in the periphery, pathogenic processes occur
in the CNS. Hence, as suggested by recent studies, it might be
more relevant to use CSF rather than serum anti-AQP4 titer
as a biomarker for the followup of NMO patients [20, 28].
Our study presented some limitations that should be
pointed out.The relative small number of patients tested may
have limited the detection of significant correlations between
immunological and clinical parameters. This study cannot
address in detail the question whether relapses are preceded
by an increase in AQP4 serum levels, since no paired samples
taken shortly before and during relapse onset were available
for comparison from most patients. Due to the retrospective
design, time intervals between the samplings and treatments
of patients were variable.The statistical results must be there-
fore interpreted with caution. However, this heterogeneity
reflects the clinical practice in which patients are not mon-
itored with short and regular intervals and receive various
drugs. At an individual level, we noted that anti-AQP4 Ab
concentration is highly variable and is related tomany factors
including the administration of immunosuppressants. How-
ever, it did not appear closely correlated with disease activity.
5. Conclusions
Altogether, our results showed that anti-AQP4 serum con-
centration in NMO patients is representative of serum com-
plement-mediated cytotoxicity.The lack of strong correlation
between the anti-AQP4 serum reactivity and disease course
in our study suggests that anti-AQP4 Ab monitoring could
not be used to reliably predict relapses and adapt treatment.
Therefore, the longitudinal evaluation of serum anti-AQP4
reactivity does not appear helpful for an accurate followup of
NMO patients in clinical practice.
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